Propanc publishes study on pancreatic proenzyme cancer treatment

Propanc Biopharma (NASDAQ:PPCB) published a peer-reviewed study in Scientific Reports on its pancreatic proenzyme combination PRP, showing anti-tumor efficacy in lab and animal models, and improved survival in human patients. The study evaluated PRP's impact on 24 cancer cell lines, with significant tumor weight reduction and no adverse events reported. The company is developing PRP for pancreatic, ovarian, and refractory prostate cancers.

Original reporting
Published Oct 14, 2026, 12:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PPCB
Bullish
medium confidence
Mentioned
$PPCB
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PPCBBullishMed
01

Why it matters

The study provides the first publicly disclosed efficacy data, which could influence the stock's valuation.

02

Market read

New clinical data may trigger short‑term buying interest in PPCB.

03

What to watch

Small patient cohort and lack of regulatory milestones reduce immediate commercial upside.

Relevance 8/10Novelty 9/10Timing: same-day release

Background

Propanc Biopharma (NASDAQ:PPCB) announced the publication of a peer‑reviewed pilot study on its PRP proenzyme combination for pancreatic, ovarian and other cancers.

Company-level read

Ticker impact

$PPCBBullishMedium confidence
Context

Propanc Biopharma published a pilot study showing 85.9% tumor‑weight reduction in a pancreatic animal model and improved survival in a patient cohort.

Expected impact

upward pressure as the market prices in the encouraging trial results

Evidence & confidence

The study is the first public disclosure of efficacy data for the PRP formulation, a material catalyst for a micro‑cap biotech.

Market effects

May boost interest in pancreatic cancer therapeutics and related biotech peers.

Limited to U.S. biotech investors; no broader regional effect.

Potentially draws attention from global oncology research investors.

Counterpoint

Data are pre‑clinical and early‑stage; efficacy may not translate to later trials.

Key entities

  • Propanc Biopharma, Inc.

    US‑listed biotech developing PRP proenzyme therapy.

Related articles

$PPCBMed

Propanc Reports PRP Activity In Pancreatic Cancer Models, Files Combination Patent Application

Propanc Biopharma (PPCB) reported that its pancreatic proenzyme formulation, PRP, reduced cancer-cell growth and invasion in preclinical studies, including in chemotherapy-resistant models. The study, conducted with Spanish universities, showed PRP alone reduced cell proliferation by 50%, with a combination treatment reducing it by up to 75%. The company filed a patent application for the combination approach and plans further validation and a Phase 1b clinical trial.

$PPCBMed

Propanc files patent for pancreatic cancer combination therapy

Propanc Biopharma (PPCB) reported preclinical study results showing its pancreatic proenzyme formulation PRP and its combination with galunisertib reduced cell proliferation and invasion in pancreatic cancer models. The company filed a patent for the combination approach and plans a Phase 1b study. PRP alone and in combination showed significant reductions in cancer cell activity.

$PPCBHigh

Propanc Biopharma Faces Nov. 2 Nasdaq Delisting Without Appeal by Oct. 30

Propanc Biopharma (PPCB) received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price requirement. The company must appeal by October 30, 2026, to avoid delisting on November 2, 2026. Propanc claims it has cured the deficiency and will request an appeal, which would stay the delisting until a panel decision. Delisting could negatively impact liquidity, market price, and access to capital markets.

$PPCBMed

Propanc Biopharma targets February 2027 for first patient screening

Propanc Biopharma (PPCB) aims to begin patient screening for its cancer treatment PPC-001 in February 2027. The Phase 1b study will involve up to 50 patients with solid tumors in Australia. The company is finalizing clinical protocols and site assessments, with regulatory submissions planned for early 2027. PPC-001 has received FDA Orphan Drug Designation for pancreatic cancer.

$PPCBMedAI 8/10

Propanc reports preclinical data on pancreatic cancer treatment

Propanc Biopharma (NASDAQ:PPCB) reported preclinical data for its pancreatic cancer treatment PRP, showing reduced cell proliferation, migration, and invasion in chemoresistant models. The study, conducted with Spanish universities, also showed upregulation of E-cadherin and EPCAM, and downregulation of Vimentin and Snail. PRP has FDA Orphan Drug Designation and a Phase 1b trial is planned for Q1 2027.